공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

수막종 : 파이프라인 리뷰

Meningioma - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 361621
페이지 정보 영문 349 Pages
가격
US $ 2,000 ₩ 2,231,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,462,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,694,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


수막종 : 파이프라인 리뷰 Meningioma - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 349 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

수막종(Meningioma) 치료제의 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

수막종 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

수막종 : 기업에서 개발중인 치료제

수막종 : 대학/기관에서 연구중인 치료제

수막종 : 파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품

수막종 : 기업에서 개발중인 제품

수막종 : 대학/기관에서 연구중인 제품

수막종 치료제 개발에 참여하고 있는 기업

  • Arno Therapeutics, Inc.
  • Boehringer Ingelheim GmbH
  • e-Therapeutics Plc
  • GlaxoSmithKline Plc
  • Novartis AG
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Progenics Pharmaceuticals, Inc.

수막종 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

수막종 : 최근의 파이프라인 동향

수막종 : 휴지중인 프로젝트

수막종 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSM 16.07.14

List of Tables

  • Number of Products under Development for Meningioma, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Meningioma - Pipeline by Advanced Accelerator Applications SA, H2 2019
  • Meningioma - Pipeline by AptaBio Therapeutics Inc, H2 2019
  • Meningioma - Pipeline by AstraZeneca Plc, H2 2019
  • Meningioma - Pipeline by BNOAT Oncology Inc, H2 2019
  • Meningioma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Meningioma - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Meningioma - Pipeline by Clarity Pharmaceuticals Pty Ltd, H2 2019
  • Meningioma - Pipeline by Eli Lilly and Co, H2 2019
  • Meningioma - Pipeline by Merck & Co Inc, H2 2019
  • Meningioma - Pipeline by Merck KGaA, H2 2019
  • Meningioma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
  • Meningioma - Pipeline by Pharma Mar SA, H2 2019
  • Meningioma - Pipeline by Progenics Pharmaceuticals Inc, H2 2019
  • Meningioma - Pipeline by Recordati SpA, H2 2019
  • Meningioma - Pipeline by Recursion Pharmaceuticals Inc, H2 2019
  • Meningioma - Dormant Projects, H2 2019
  • Meningioma - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Meningioma, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningioma - Pipeline Review, H2 2019, provides an overview of the Meningioma (Oncology) pipeline landscape.

A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of brain tumor is about three times more common in women than in men. A meningioma can cause symptoms by pressing on the brain or spinal cord.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meningioma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Meningioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meningioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 7, 4, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Meningioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Meningioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Meningioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Meningioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Meningioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Meningioma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Meningioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Meningioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Meningioma - Overview
    • Meningioma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Meningioma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Meningioma - Companies Involved in Therapeutics Development
    • Advanced Accelerator Applications SA
    • AptaBio Therapeutics Inc
    • AstraZeneca Plc
    • BNOAT Oncology Inc
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Co
    • Clarity Pharmaceuticals Pty Ltd
    • Eli Lilly and Co
    • Merck & Co Inc
    • Merck KGaA
    • Ono Pharmaceutical Co Ltd
    • Pharma Mar SA
    • Progenics Pharmaceuticals Inc
    • Recordati SpA
    • Recursion Pharmaceuticals Inc
  • Meningioma - Drug Profiles
  • Meningioma - Dormant Projects
  • Meningioma - Discontinued Products
  • Meningioma - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q